Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a pioneering biotechnology company dedicated to developing RNA interference (RNAi) therapeutics. Established in 2002, Alnylam aims to harness the power of RNAi to treat genetic diseases by targeting and silencing specific genes responsible for the production of disease-causing proteins. The company's innovative approach has positioned it as a leader in the field of genetic medicine.

The company is committed to advancing its robust pipeline of investigational medicines, focusing on rare genetic diseases, cardio-metabolic diseases, and central nervous system or ocular diseases. By leveraging its expertise in RNAi, Alnylam seeks to address unmet medical needs and offer new treatment options for patients who have limited or no alternatives.

Alnylam's efforts extend beyond drug discovery and development. The company actively collaborates with healthcare professionals, patients, and advocacy groups to improve patient access to its therapies. With a strong emphasis on scientific innovation and patient-centric care, Alnylam is dedicated to transforming the treatment landscape for genetic disorders worldwide.